We report a 74-year-old 
Introduction

Primary lymphoma of bone (PLB) is a rare disease that accounts for 1-2% of all malignant lymphoma and 3-5% of all extranodal lymphoma (1), and initial involvement of the temporal bone is even rarer. The most common sites involved in PLB are the extremities, particularly the femur (1-3). Diffuse large B-cell lymphoma (DLBCL) is the most commom type of malignant lymphoma, representing 30-40% of adult cases, and is regarded as a heterogeneous group of lymphoma in surface markers, histology, and clinical features
.
CD5 is a cell surface molecule expressed on most T cells and a subset of B cells. Among B-cell malignancies, CD5 is mainly expressed in chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Recently, CD5-positive DLBCL with no past history of lymphoproliferative disorder (de novo CD5
+ DLBCL) is regarded as a distinct subtype of DLBCL (6) (7) (8) i g u r e 1 . A) S o f t t i s s u e wi n d o w CT s h o we d a n e n h a n c e d ma s s i n t h e l e f t t e mp o r a l mu s c l e , t h e l a t e r a l p t e r y g o i d mu sc l e , t h e mi d d l e f o s s a , t h e ma s t o i d a i r c e l l s , a n d t h e mi d d l e e a r ( a r r o ws ) . B ) Ax i a l T 2 -we i g h t e d MRI s h o we d a ma s s ( a r r o ws ) d e s t r o y i n g t h e l e f t t e mp o r a l b o n e , wi t h i n v o l v e me n t o f t h e o v e r l y i n g t e mp o r a l mu s c l e , s u b c u t a n e o u s t i s s u e , a n d s u bd u r a l s p a c e .
F i g u r e 2 . Ot o s c o p i c e x a mi n a t i o n r e v e a l e d a s o f t ma s s f r o m t h e u p p e r wa l l o f t h e l e f t e x t e r n a l a u d i t o r y c a n a l .
loss) according to the Ann Arbor classification.
Laboratory studies on admission showed a red blood cell count of 349×10 4 (Fig. 2) . The tympanic membrane was normal. Biopsy specimens of the mass showed diffuse proliferation of abnormal large lymphoid cells (Fig. 3A) . Immunohistochemical staining using frozen sections showed that the lymphoma cells were positive for CD5, CD20, CD21, and negative for CD3, CD10, CD23, BCL2, and cyclin D1 (Fig. 3BCD) 
h e t u mo r f r o m t h e l e f t e x t e r n a l a u d i t o r y c a n a l . A) Di f f u s e i n f i l t r a t i o n o f l a r g e -s i z e d l y mp h o i d c e l l s wa s s h o wn ( He ma t o x y l i n -e o s i n ( HE ) s t a i n , × 2 0 0 ) . B ) , C) , D) T u mo r c e l l s
we r e p o s i t i v e f o r CD5 a n d CD2 0 , a n d n e g a t i v e f o r CD3 ( × 2 0 0 ) . (10) . Currently, the criteria adopted by the World Health Organization are the following: 1) a single skeletal site, with or without regional lymph node involvement; 2) multiple bones are involved, but there is no visceral or lymph node involvement (11) .
T a b l e 1 . S u mma r y o f P r i ma r y L y mp h o ma o f t h e T e mp o r a l B o n e achieved complete remission. She is alive and well without any therapy 33 months after the diagnosis.
Discussion
PLB is a rare disease accounting for 1-2% of all malignant lymphoma and 3-5% of all extranodal lymphoma (1). The diagnostic criteria for PLB have been developed from those enumerated by Coley et al in 1950 and are as follows: 1) clinically a primary focus in a single bone on admission, 2) unequivocal histologic proof from the bone lesion, 3) metastases present on admission only if regional, or if the onset of symptoms of the primary tumor preceded the appearance of the metastases by at least six months
PLB may occur in patients of any age group but has a tendency of adult onset and a male predominance (male-tofemale ratio ranges from 1.5-2: 1) (2, 3, 11) . The most common initial symptom is localized pain, and patients sometimes present with a palpable mass (1) (2) (3) 10) . Patients rarely present with systemic symptoms, such as fever or night sweating (1, 2, 11) . On conventional X-ray, PLB shows lytic, sclerotic, permeative lesions, or a combination of these (1) . CT (1-3, 10, 11) . It is considered that PLB usually requires radiotherapy with chemotherapy (3) . Generally, the prognosis of PLB is favorable, and the 5-year overall survival is approximately 60% (2, 11, 12) .
and MRI are useful for the diagnosis of PLB. However, on follow-up examinations, MRI is not useful to differentiate between persistent disease and healing bone (3). Positron emission tomography with fluorine 18-fluorodeoxyglucose (FDG-PET) may be preferable for the assessment of remission status. Histopathologically, PLB is usually diagnosed as DLBCL
The most common sites involved in PLB are the extremities, particularly the femur (1-3) , and initial involvement of the temporal bone is extremely rare. We found only 17 reported cases of primary temporal bone lymphoma in the English and Japanese literature, including the cases of primary lymphoma of the middle ear (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (13, 15, 20, 23 
